Stock Events

Stock Events

Oxford Biomedica 

GBX560
79
-GBX9-1.58% Thursday 15:30

Statistics

Day High
563
Day Low
542
52W High
962
52W Low
232.5
Volume
123,316.41
Avg. Volume
-
Mkt Cap
594.37M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26MarExpected
Q4 2023
Q1 2024
Q1 2024
Q2 2024
Q1 2025
Q2 2025
Q4 2025
-114.95
-76.63
-38.32
0
Expected EPS
-8.01872516352
Actual EPS
-5.4535410432

Financials

-37.74%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
25.76BRevenue
-9.72BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OXB.LSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on gene therapy products for rare diseases, directly competing with Oxford Biomedica's gene therapy solutions.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics works on genomic medicine, including gene therapy, competing in the same advanced therapy medicinal products (ATMPs) space as Oxford Biomedica.
Pfizer
PFE
Mkt Cap161.09B
Pfizer, through its acquisition of Bamboo Therapeutics and Spark Therapeutics, has expanded into gene therapy, making it a competitor in the same market as Oxford Biomedica.
Novartis
NVS
Mkt Cap297.32B
Novartis, with its acquisition of AveXis, competes in the gene therapy market, particularly in treatments for spinal muscular atrophy, a direct competition to Oxford Biomedica's offerings.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space, which is closely related to Oxford Biomedica's viral vector development for gene therapy.
uniQure N.V.
QURE
Mkt Cap4.17B
uniQure is involved in developing gene therapies for hemophilia and other genetic diseases, competing in the same therapeutic areas as Oxford Biomedica.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO is a biotechnology company specializing in the development of gene therapy products, using its NAV Technology Platform that competes with Oxford Biomedica's LentiVector platform.

About

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Show more...
CEO
Dr. Frank Mathias
Employees
900
Country
GB
ISIN
GB00BDFBVT43

Listings

LSE
GB
OXB.LSE
OTC Link
US
OXBDF
F
DE
OXOA.F

0 Comments

Share your thoughts

FAQ

What is Oxford Biomedica stock price today?▼
The current price of OXB.LSE is GBX560 GBX — it has decreased by -1.58% in the past 24 hours. Watch Oxford Biomedica stock price performance more closely on the chart.
What is Oxford Biomedica stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oxford Biomedica stocks are traded under the ticker OXB.LSE.
Is Oxford Biomedica stock price growing?▼
OXB.LSE stock has risen by +1.63% compared to the previous week, the month change is a -10.26% fall, over the last year Oxford Biomedica has showed a +112.52% increase.
What is Oxford Biomedica market cap?▼
Today Oxford Biomedica has the market capitalization of 594.37M
When is the next Oxford Biomedica earnings date?▼
Oxford Biomedica is going to release the next earnings report on September 23, 2026.
What were Oxford Biomedica earnings last quarter?▼
OXB.LSE earnings for the last quarter are -5.45 GBX per share, whereas the estimation was -8.02 GBX resulting in a +31.99% surprise. The estimated earnings for the next quarter are N/A GBX per share.
What is Oxford Biomedica revenue for the last year?▼
Oxford Biomedica revenue for the last year amounts to 25.76B GBX.
What is Oxford Biomedica net income for the last year?▼
OXB.LSE net income for the last year is -9.72B GBX.
How many employees does Oxford Biomedica have?▼
As of April 06, 2026, the company has 900 employees.
In which sector is Oxford Biomedica located?▼
Oxford Biomedica operates in the Health Care sector.
When did Oxford Biomedica complete a stock split?▼
The last stock split for Oxford Biomedica was on May 30, 2018 with a ratio of 1:50.
Where is Oxford Biomedica headquartered?▼
Oxford Biomedica is headquartered in Oxford, GB.